Trial · NCT01873859
Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
NCT01873859, Not applicable, Completed, Shahid Beheshti University of Medical Sciences; results first posted 2014-06-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media. Trials, record NCT01873859. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01873859
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media
- NCT number
- NCT01873859
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 166 participants, actual
- Lead sponsor
- Shahid Beheshti University of Medical Sciences
- Conditions
- Diabetes Mellitus, Lactic Acidosis
- Interventions
- Metformin
- First posted
- 2013-06-10
- Last updated
- 2014-06-16
- Results first posted
- 2014-06-16
- Limitations and caveats
- unable to follow patient's creatinine and acidosis for more than 48 hr.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Lactic Acidosis | 48 hrs | Metformin-associated lactic acidosis (MALA) was defined as an arterial pH \<7.35 and plasma lactate concentration \>5 mmol ⁄ L. |
| Primary | Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use. | 48 hours from the baseline |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Lactic Acidosis | 48 hrs | participants | NUMBER | |
| PRIMARY | Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use. | 48 hours from the baseline | mg/dl | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Lactic Acidosis | On-metformin | 0 | participants | ||
| Incidence of Lactic Acidosis | Off-metformin | 0 | participants | ||
| Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use. | On-metformin | 1.05 | Standard Deviation 0.116 | mg/dl | |
| Change of Baseline Creatinine 48 hr After Recieving Contrast Media in the Presence or Absence of Metformin Use. | Off-metformin | 0.99 | Standard Deviation 0.159 | mg/dl |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | On-metformin | 83 | |
| Overall Study | STARTED | Off-metformin | 83 | |
| Overall Study | COMPLETED | On-metformin | 83 | |
| Overall Study | COMPLETED | Off-metformin | 79 | |
| Overall Study | NOT COMPLETED | On-metformin | 0 | |
| Overall Study | NOT COMPLETED | Off-metformin | 4 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | On-metformin | ||
| Total, all-cause mortality | Off-metformin | ||
| Total, other adverse events | On-metformin | 0 | 83 |
| Total, other adverse events | Off-metformin | 0 | 79 |
| Total, serious adverse events | On-metformin | 0 | 83 |
| Total, serious adverse events | Off-metformin | 0 | 79 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20032157 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| On-metformin vs Off-metformin: Incidence of Lactic Acidosis | Trial comparisons |
| On-metformin vs Off-metformin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01873859
GET https://conductscience.org/api/trials/v1/NCT01873859/registered